NO308611B1 - AnalogifremgangsmÕte for fremstilling av et terapeutisk aktivt peptid - Google Patents

AnalogifremgangsmÕte for fremstilling av et terapeutisk aktivt peptid Download PDF

Info

Publication number: NO308611B1
Authority: NO; Norway
Prior art keywords: mbp; cells; peptide; patients; tcr
Prior art date: 1990-03-30

Application number

NO923778A

Other languages

English (en)

Norwegian (no)

Other versions

NO923778D0 (no

NO923778L (no

Inventor

Kai W Wucherpfenning

Howard L Weiner

David Allen Hafler

Original Assignee

Brigham & Womens Hospital

Autoimmune Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-30

Filing date

1992-09-29

Publication date

2000-10-02

1992-09-29 Application filed by Brigham & Womens Hospital, Autoimmune Inc filed Critical Brigham & Womens Hospital

1992-09-29 Publication of NO923778D0 publication Critical patent/NO923778D0/no

1992-11-16 Publication of NO923778L publication Critical patent/NO923778L/no

2000-10-02 Publication of NO308611B1 publication Critical patent/NO308611B1/no

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 76
238000004519 manufacturing process Methods 0.000 title claims description 5
210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 131
201000006417 multiple sclerosis Diseases 0.000 claims abstract description 79
238000000034 method Methods 0.000 claims abstract description 21
239000007790 solid phase Substances 0.000 claims description 4
230000002194 synthesizing effect Effects 0.000 claims description 2
239000007858 starting material Substances 0.000 claims 1
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 abstract description 106
102000047918 Myelin Basic Human genes 0.000 abstract description 67
101710107068 Myelin basic protein Proteins 0.000 abstract description 67
102000004196 processed proteins & peptides Human genes 0.000 abstract description 34
101001018318 Homo sapiens Myelin basic protein Proteins 0.000 abstract description 11
239000003795 chemical substances by application Substances 0.000 abstract description 11
102000054064 human MBP Human genes 0.000 abstract description 11
239000003814 drug Substances 0.000 abstract description 10
230000028993 immune response Effects 0.000 abstract description 9
230000002238 attenuated effect Effects 0.000 abstract description 5
229940124597 therapeutic agent Drugs 0.000 abstract description 5
-1 vaccines Proteins 0.000 abstract description 2
238000009007 Diagnostic Kit Methods 0.000 abstract 1
238000002405 diagnostic procedure Methods 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1
108700018351 Major Histocompatibility Complex Proteins 0.000 description 36
108090000623 proteins and genes Proteins 0.000 description 33
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 31
201000010099 disease Diseases 0.000 description 28
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
210000004027 cell Anatomy 0.000 description 21
239000000427 antigen Substances 0.000 description 20
108091007433 antigens Proteins 0.000 description 20
102000036639 antigens Human genes 0.000 description 20
208000024891 symptom Diseases 0.000 description 18
238000011282 treatment Methods 0.000 description 15
210000000612 antigen-presenting cell Anatomy 0.000 description 13
230000009257 reactivity Effects 0.000 description 12
208000023275 Autoimmune disease Diseases 0.000 description 11
108091008874 T cell receptors Proteins 0.000 description 11
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 11
150000001413 amino acids Chemical group 0.000 description 11
239000012634 fragment Substances 0.000 description 10
108020004414 DNA Proteins 0.000 description 9
241000124008 Mammalia Species 0.000 description 9
201000002491 encephalomyelitis Diseases 0.000 description 9
241000699666 Mus <mouse, genus> Species 0.000 description 8
210000005087 mononuclear cell Anatomy 0.000 description 8
238000004458 analytical method Methods 0.000 description 7
102000054766 genetic haplotypes Human genes 0.000 description 7
210000005259 peripheral blood Anatomy 0.000 description 7
239000011886 peripheral blood Substances 0.000 description 7
238000003752 polymerase chain reaction Methods 0.000 description 7
230000000638 stimulation Effects 0.000 description 7
238000002105 Southern blotting Methods 0.000 description 6
230000003321 amplification Effects 0.000 description 6
210000003169 central nervous system Anatomy 0.000 description 6
230000000694 effects Effects 0.000 description 6
230000001712 encephalitogenic effect Effects 0.000 description 6
238000003199 nucleic acid amplification method Methods 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
239000003153 chemical reaction reagent Substances 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 5
230000006870 function Effects 0.000 description 5
230000001939 inductive effect Effects 0.000 description 5
239000000047 product Substances 0.000 description 5
241000894007 species Species 0.000 description 5
241000282412 Homo Species 0.000 description 4
238000012408 PCR amplification Methods 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
238000010171 animal model Methods 0.000 description 4
210000002443 helper t lymphocyte Anatomy 0.000 description 4
210000000987 immune system Anatomy 0.000 description 4
210000002540 macrophage Anatomy 0.000 description 4
235000018102 proteins Nutrition 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
102000000588 Interleukin-2 Human genes 0.000 description 3
108010002350 Interleukin-2 Proteins 0.000 description 3
102000055324 Myelin Proteolipid Human genes 0.000 description 3
108700021862 Myelin Proteolipid Proteins 0.000 description 3
208000012902 Nervous system disease Diseases 0.000 description 3
208000025966 Neurological disease Diseases 0.000 description 3
241000700159 Rattus Species 0.000 description 3
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
238000010804 cDNA synthesis Methods 0.000 description 3
238000010370 cell cloning Methods 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
238000011694 lewis rat Methods 0.000 description 3
238000002595 magnetic resonance imaging Methods 0.000 description 3
239000013642 negative control Substances 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
238000005457 optimization Methods 0.000 description 3
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
238000011160 research Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
101150084750 1 gene Proteins 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 2
206010062016 Immunosuppression Diseases 0.000 description 2
102000004388 Interleukin-4 Human genes 0.000 description 2
108090000978 Interleukin-4 Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
102000043131 MHC class II family Human genes 0.000 description 2
108091054438 MHC class II family Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
101150117115 V gene Proteins 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
125000000539 amino acid group Chemical group 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000001363 autoimmune Effects 0.000 description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
230000033228 biological regulation Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000010276 construction Methods 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
229940028885 interleukin-4 Drugs 0.000 description 2
239000000463 material Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000002953 phosphate buffered saline Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
238000010532 solid phase synthesis reaction Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
210000004885 white matter Anatomy 0.000 description 2
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
WQKAQKZRDIZYNV-VZFHVOOUSA-N Ala-Ser-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O WQKAQKZRDIZYNV-VZFHVOOUSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
IWLZBRTUIVXZJD-OLHMAJIHSA-N Asp-Thr-Asp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O IWLZBRTUIVXZJD-OLHMAJIHSA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
108010041397 CD4 Antigens Proteins 0.000 description 1
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
208000016192 Demyelinating disease Diseases 0.000 description 1
206010012305 Demyelination Diseases 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
108010064885 HLA-DR3 Antigen Proteins 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
JRHFQUPIZOYKQP-KBIXCLLPSA-N Ile-Ala-Glu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O JRHFQUPIZOYKQP-KBIXCLLPSA-N 0.000 description 1
102100034343 Integrase Human genes 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
GPJGFSFYBJGYRX-YUMQZZPRSA-N Lys-Gly-Asp Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O GPJGFSFYBJGYRX-YUMQZZPRSA-N 0.000 description 1
LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
108700005092 MHC Class II Genes Proteins 0.000 description 1
108010090054 Membrane Glycoproteins Proteins 0.000 description 1
102000012750 Membrane Glycoproteins Human genes 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
241001529936 Murinae Species 0.000 description 1
101001018320 Mus musculus Myelin basic protein Proteins 0.000 description 1
101100096028 Mus musculus Smok1 gene Proteins 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
238000010222 PCR analysis Methods 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108010010974 Proteolipids Proteins 0.000 description 1
102000016202 Proteolipids Human genes 0.000 description 1
238000002123 RNA extraction Methods 0.000 description 1
239000013614 RNA sample Substances 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
108700042075 T-Cell Receptor Genes Proteins 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
VTIAEOKFUJJBTC-YDHLFZDLSA-N Val-Tyr-Asp Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VTIAEOKFUJJBTC-YDHLFZDLSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
230000009798 acute exacerbation Effects 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229940037003 alum Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
108010047857 aspartylglycine Proteins 0.000 description 1
108010092854 aspartyllysine Proteins 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
210000003426 epidermal langerhans cell Anatomy 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
210000000285 follicular dendritic cell Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
108010087823 glycyltyrosine Proteins 0.000 description 1
208000024908 graft versus host disease Diseases 0.000 description 1
ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
239000000833 heterodimer Substances 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
210000003917 human chromosome Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
229940073062 imuran Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000001821 langerhans cell Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
230000002297 mitogenic effect Effects 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000002864 mononuclear phagocyte Anatomy 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
238000002205 phenol-chloroform extraction Methods 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000011552 rat model Methods 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000009711 regulatory function Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000002992 thymic effect Effects 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
239000013598 vector Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Animal Behavior & Ethology (AREA)
Analytical Chemistry (AREA)
Genetics & Genomics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Biochemistry (AREA)
Neurology (AREA)
Biophysics (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Cell Biology (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Pathology (AREA)
Psychiatry (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)

NO923778A 1990-03-30 1992-09-29 AnalogifremgangsmÕte for fremstilling av et terapeutisk aktivt peptid NO308611B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US50255990A	1990-03-30	1990-03-30
PCT/US1991/002218 WO1991015225A1 (en)	1990-03-30	1991-03-29	Multiple sclerosis t-cell receptor

Publications (3)

Publication Number	Publication Date
NO923778D0 NO923778D0 (no)	1992-09-29
NO923778L NO923778L (no)	1992-11-16
NO308611B1 true NO308611B1 (no)	2000-10-02

Family

ID=23998362

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO923778A NO308611B1 (no)	1990-03-30	1992-09-29	AnalogifremgangsmÕte for fremstilling av et terapeutisk aktivt peptid

Country Status (13)

Country	Link
EP (1)	EP0522091B9 (de)
JP (1)	JPH05507911A (de)
AT (1)	ATE210721T1 (de)
AU (1)	AU651350B2 (de)
BR (1)	BR9106303A (de)
CA (1)	CA2078549C (de)
DE (1)	DE69132863T2 (de)
DK (1)	DK0522091T5 (de)
ES (1)	ES2169021T3 (de)
HU (1)	HU217847B (de)
IL (3)	IL165071A (de)
NO (1)	NO308611B1 (de)
WO (1)	WO1991015225A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6221352B1 (en)	1989-03-21	2001-04-24	The Immune Response Corporation	Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US6207645B1 (en)	1989-03-21	2001-03-27	The Immune Response Corporation	Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
DE69121099T3 (de) *	1990-05-01	2001-01-25	The Board Of Trustees Of The Leland S. Stanford Junior University, Stanford	Stoffgemische zur Anwendung in einem Verfahren zur Behandlung eines an multipler Sklerose leidenden Menschen
IL99699A (en)	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH06507384A (ja) *	1991-01-22	1994-08-25	ザ　イミューン　レスポンス　コーポレイション	特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
US6252040B1 (en)	1991-10-22	2001-06-26	The Governors Of The University Of Alberta	Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5817629A (en)	1991-10-22	1998-10-06	The Governors Of The University Of Alberta	Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
JPH07506563A (ja) *	1991-12-24	1995-07-20	ザ　イミューン　レスポンス　コーポレイション	特異的ｔ細胞群による病原応答に起因する疾患に対してのワクチン接種および方法
US5891435A (en) *	1993-04-16	1999-04-06	Research Corporation Technologies, Inc.	Methods and compositions for delaying or preventing the onset of autoimmune disease
AU2950195A (en) *	1994-07-01	1996-01-25	Connective Therapeutics Inc.	Methods for diagnosing an immune-related disease and choosing an immune-related therapy
CZ122697A3 (en) *	1994-10-25	1997-09-17	Immulogic Pharma Corp	Preparations and methods of treating disseminated sclerosis
IL114458A0 (en) *	1995-07-05	1995-11-27	Yeda Res & Dev	Therapeutic preparations for treatment of T cell mediated diseases
US6488933B2 (en)	1995-07-05	2002-12-03	Yeda Research And Development Co. Ltd.	Preparations for the treatment of T cell mediated diseases
US20020009448A1 (en) *	1997-09-19	2002-01-24	Leslie P. Weiner	T-cell vaccination for the treatment of multiple sclerosis
ATE367823T1 (de)	2000-05-24	2007-08-15	Us Health	E-selectin zur behandlung oder vorbeugung von schlaganfall
SI1731912T1 (sl) *	2000-08-21	2014-05-30	Apitope Technology (Bristol) Limited	Postopek izbire peptida
US7658926B2 (en)	2001-09-14	2010-02-09	Opexa Pharmaceuticals, Inc.	Autologous T-cell vaccines materials and methods
CA2485874A1 (en) *	2002-06-05	2003-12-18	Baylor College Of Medicine	T cell receptor cdr3 sequences and methods for detection
US7744893B2 (en)	2002-06-05	2010-06-29	Baylor College Of Medicine	T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same
RU2327487C2 (ru)	2002-08-08	2008-06-27	Бейлор Колледж Оф Медисин	Выделение и идентификация т-клеток

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2072356A1 (en) *	1989-12-29	1991-06-30	James L. Urban	Diagnosis and treatment of diseases

1991
- 1991-03-28 IL IL165071A patent/IL165071A/en not_active IP Right Cessation
- 1991-03-28 IL IL9770991A patent/IL97709A/xx not_active IP Right Cessation
- 1991-03-29 ES ES91910085T patent/ES2169021T3/es not_active Expired - Lifetime
- 1991-03-29 AU AU78989/91A patent/AU651350B2/en not_active Expired
- 1991-03-29 WO PCT/US1991/002218 patent/WO1991015225A1/en not_active Ceased
- 1991-03-29 BR BR919106303A patent/BR9106303A/pt not_active Application Discontinuation
- 1991-03-29 DE DE69132863T patent/DE69132863T2/de not_active Expired - Lifetime
- 1991-03-29 HU HU9203100A patent/HU217847B/hu unknown
- 1991-03-29 AT AT91910085T patent/ATE210721T1/de not_active IP Right Cessation
- 1991-03-29 EP EP91910085A patent/EP0522091B9/de not_active Expired - Lifetime
- 1991-03-29 CA CA002078549A patent/CA2078549C/en not_active Expired - Lifetime
- 1991-03-29 JP JP91509347A patent/JPH05507911A/ja active Pending
- 1991-03-29 DK DK91910085T patent/DK0522091T5/da active
1992
- 1992-09-29 NO NO923778A patent/NO308611B1/no not_active IP Right Cessation
2004
- 2004-11-07 IL IL16507104A patent/IL165071A0/xx active IP Right Grant

Also Published As

Publication number	Publication date
HUT63334A (en)	1993-08-30
NO923778D0 (no)	1992-09-29
ATE210721T1 (de)	2001-12-15
JPH05507911A (ja)	1993-11-11
DE69132863T2 (de)	2002-06-20
AU651350B2 (en)	1994-07-21
IL165071A (en)	2008-06-05
IL165071A0 (en)	2005-12-18
DE69132863D1 (de)	2002-01-24
ES2169021T3 (es)	2002-07-01
IL97709A (en)	2005-05-17
HU9203100D0 (en)	1992-12-28
CA2078549C (en)	2006-07-11
DK0522091T3 (da)	2002-04-08
WO1991015225A1 (en)	1991-10-17
EP0522091A1 (de)	1993-01-13
EP0522091A4 (en)	1993-05-26
AU7898991A (en)	1991-10-30
HU217847B (hu)	2000-04-28
EP0522091B9 (de)	2007-11-21
IL97709A0 (en)	1992-06-21
DK0522091T5 (da)	2008-06-23
BR9106303A (pt)	1993-04-13
NO923778L (no)	1992-11-16
CA2078549A1 (en)	1991-10-01
EP0522091B1 (de)	2001-12-12

Legal Events

Date	Code	Title	Description
2011-04-18	MK1K	Patent expired

Publication	Publication Date	Title
NO308611B1 (no)	2000-10-02	AnalogifremgangsmÕte for fremstilling av et terapeutisk aktivt peptid
Steinman	2015	The T lymphocyte in experimental allergic encephalomyelitis
Todd et al.	1988	A molecular basis for MHC class II—associated autoimmunity
Martin et al.	1995	Immunological aspects of experimental allergic encephalomyelitis and multiple sclerosis
US7084247B2 (en)	2006-08-01	Identification of self and non-self antigens implicated in autoimmune diseases
Steinman	1991	The development of rational strategies for selective immunotherapy against autoimmune demyelinating disease
JPH0272197A (ja)	1990-03-12	自己免疫疾患の処置としての抗―ｔ細胞レセプター決定基
EP0650498B1 (de)	1998-09-09	Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
HUT77047A (hu)	1998-03-02	Szklerózis multiplex kezelésére szolgáló készítmények és kezelések
US6039947A (en)	2000-03-21	Peptides derived from immunodominant epitopes of myelin basic protein
CN101484183B (zh)	2016-08-10	Hla肽疗法
HUT77484A (hu)	1998-05-28	Peptidek és ezeket tartalmazó gyógyszerkészítmények
JPH11507354A (ja)	1999-06-29	自己免疫疾患処置のためのｍｈｃクラスｉｉ分子のペプチドを用いるワクチン接種
EP0527199A1 (de)	1993-02-17	Variable transskripte von t-zellen als marker für krankheiten.
JPH08509204A (ja)	1996-10-01	自己免疫疾患の治療のためのｍｈｃクラス▲ｉｉ▼分子のペプチドを用いた予防接種
Breiteneder et al.	1996	Sequence comparisons of the CDR3 hyper-variable loops of human T cell receptors specific for three major T cell epitopes of the birch pollen allergen Bet v 1
AU4920093A (en)	1994-04-12	Reagents and methods for treating rheumatoid arthritis
Bauer et al.	0	Workshop N Autoimmunity